The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chronic Spontaneous Urticaria Drug Treatment Market Research Report 2024
Synopsis
Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, is defined as the presence of urticaria most of the time during a week and this condition lasts for 6 weeks or more. About 40% of patients are accompanied by angioedema. The standard treatment for CSU is mainly second-generation H1 antihistamines, often at higher than conventional doses, combined with H2 antihistamines and leukotriene modulators.
The global Chronic Spontaneous Urticaria Drug Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
CSU is a chronic inflammatory skin disease characterized by the sudden onset of hives and/or deep swelling of the skin. Despite standard of care treatments, patients with CSU often experience symptoms such as persistent itching or burning sensations that can be debilitating and significantly impact quality of life. Swelling usually occurs on the face, hands, and feet and can also affect the throat and upper respiratory tract. CSU is commonly treated with antihistamines, but in patients with limited available treatment options, the condition remains uncontrolled in up to 50% of patients.
This report aims to provide a comprehensive presentation of the global market for Chronic Spontaneous Urticaria Drug Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Spontaneous Urticaria Drug Treatment.
The Chronic Spontaneous Urticaria Drug Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Spontaneous Urticaria Drug Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Spontaneous Urticaria Drug Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Mylan N. V.
Sanofi
GlaxoSmithKline
Bayer
Merck
Aurobindo Pharma
Hikma Pharmaceuticals
WOCKHARDT
AbbVie, Inc.
Cipla Inc.
F. Hoffmann La Roche Ltd.
Teva Pharmaceutical Industries, Ltd.
Pfizer, Inc.
Novartis AG
Eli Lilly and Company
Allergan
Lupin
Segment by Type
Antihistamine
Dupixent
Other
Segment by Application
Children
Adult
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Spontaneous Urticaria Drug Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, is defined as the presence of urticaria most of the time during a week and this condition lasts for 6 weeks or more. About 40% of patients are accompanied by angioedema. The standard treatment for CSU is mainly second-generation H1 antihistamines, often at higher than conventional doses, combined with H2 antihistamines and leukotriene modulators.
The global Chronic Spontaneous Urticaria Drug Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
CSU is a chronic inflammatory skin disease characterized by the sudden onset of hives and/or deep swelling of the skin. Despite standard of care treatments, patients with CSU often experience symptoms such as persistent itching or burning sensations that can be debilitating and significantly impact quality of life. Swelling usually occurs on the face, hands, and feet and can also affect the throat and upper respiratory tract. CSU is commonly treated with antihistamines, but in patients with limited available treatment options, the condition remains uncontrolled in up to 50% of patients.
This report aims to provide a comprehensive presentation of the global market for Chronic Spontaneous Urticaria Drug Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Spontaneous Urticaria Drug Treatment.
The Chronic Spontaneous Urticaria Drug Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Spontaneous Urticaria Drug Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Spontaneous Urticaria Drug Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Mylan N. V.
Sanofi
GlaxoSmithKline
Bayer
Merck
Aurobindo Pharma
Hikma Pharmaceuticals
WOCKHARDT
AbbVie, Inc.
Cipla Inc.
F. Hoffmann La Roche Ltd.
Teva Pharmaceutical Industries, Ltd.
Pfizer, Inc.
Novartis AG
Eli Lilly and Company
Allergan
Lupin
Segment by Type
Antihistamine
Dupixent
Other
Segment by Application
Children
Adult
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Spontaneous Urticaria Drug Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Spontaneous Urticaria Drug Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antihistamine
1.2.3 Dupixent
1.2.4 Other
1.3 Market by Application
1.3.1 Global Chronic Spontaneous Urticaria Drug Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Children
1.3.3 Adult
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Spontaneous Urticaria Drug Treatment Market Perspective (2019-2030)
2.2 Global Chronic Spontaneous Urticaria Drug Treatment Growth Trends by Region
2.2.1 Global Chronic Spontaneous Urticaria Drug Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Chronic Spontaneous Urticaria Drug Treatment Historic Market Size by Region (2019-2024)
2.2.3 Chronic Spontaneous Urticaria Drug Treatment Forecasted Market Size by Region (2025-2030)
2.3 Chronic Spontaneous Urticaria Drug Treatment Market Dynamics
2.3.1 Chronic Spontaneous Urticaria Drug Treatment Industry Trends
2.3.2 Chronic Spontaneous Urticaria Drug Treatment Market Drivers
2.3.3 Chronic Spontaneous Urticaria Drug Treatment Market Challenges
2.3.4 Chronic Spontaneous Urticaria Drug Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Spontaneous Urticaria Drug Treatment Players by Revenue
3.1.1 Global Top Chronic Spontaneous Urticaria Drug Treatment Players by Revenue (2019-2024)
3.1.2 Global Chronic Spontaneous Urticaria Drug Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Chronic Spontaneous Urticaria Drug Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Chronic Spontaneous Urticaria Drug Treatment Revenue
3.4 Global Chronic Spontaneous Urticaria Drug Treatment Market Concentration Ratio
3.4.1 Global Chronic Spontaneous Urticaria Drug Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Spontaneous Urticaria Drug Treatment Revenue in 2023
3.5 Global Key Players of Chronic Spontaneous Urticaria Drug Treatment Head office and Area Served
3.6 Global Key Players of Chronic Spontaneous Urticaria Drug Treatment, Product and Application
3.7 Global Key Players of Chronic Spontaneous Urticaria Drug Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Spontaneous Urticaria Drug Treatment Breakdown Data by Type
4.1 Global Chronic Spontaneous Urticaria Drug Treatment Historic Market Size by Type (2019-2024)
4.2 Global Chronic Spontaneous Urticaria Drug Treatment Forecasted Market Size by Type (2025-2030)
5 Chronic Spontaneous Urticaria Drug Treatment Breakdown Data by Application
5.1 Global Chronic Spontaneous Urticaria Drug Treatment Historic Market Size by Application (2019-2024)
5.2 Global Chronic Spontaneous Urticaria Drug Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Chronic Spontaneous Urticaria Drug Treatment Market Size (2019-2030)
6.2 North America Chronic Spontaneous Urticaria Drug Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2019-2024)
6.4 North America Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Spontaneous Urticaria Drug Treatment Market Size (2019-2030)
7.2 Europe Chronic Spontaneous Urticaria Drug Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2019-2024)
7.4 Europe Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Market Size (2019-2030)
8.2 Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Spontaneous Urticaria Drug Treatment Market Size (2019-2030)
9.2 Latin America Chronic Spontaneous Urticaria Drug Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2019-2024)
9.4 Latin America Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Spontaneous Urticaria Drug Treatment Market Size (2019-2030)
10.2 Middle East & Africa Chronic Spontaneous Urticaria Drug Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Mylan N. V.
11.1.1 Mylan N. V. Company Details
11.1.2 Mylan N. V. Business Overview
11.1.3 Mylan N. V. Chronic Spontaneous Urticaria Drug Treatment Introduction
11.1.4 Mylan N. V. Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.1.5 Mylan N. V. Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Chronic Spontaneous Urticaria Drug Treatment Introduction
11.2.4 Sanofi Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.2.5 Sanofi Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Details
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Chronic Spontaneous Urticaria Drug Treatment Introduction
11.3.4 GlaxoSmithKline Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.3.5 GlaxoSmithKline Recent Development
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Bayer Business Overview
11.4.3 Bayer Chronic Spontaneous Urticaria Drug Treatment Introduction
11.4.4 Bayer Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.4.5 Bayer Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Chronic Spontaneous Urticaria Drug Treatment Introduction
11.5.4 Merck Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.5.5 Merck Recent Development
11.6 Aurobindo Pharma
11.6.1 Aurobindo Pharma Company Details
11.6.2 Aurobindo Pharma Business Overview
11.6.3 Aurobindo Pharma Chronic Spontaneous Urticaria Drug Treatment Introduction
11.6.4 Aurobindo Pharma Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.6.5 Aurobindo Pharma Recent Development
11.7 Hikma Pharmaceuticals
11.7.1 Hikma Pharmaceuticals Company Details
11.7.2 Hikma Pharmaceuticals Business Overview
11.7.3 Hikma Pharmaceuticals Chronic Spontaneous Urticaria Drug Treatment Introduction
11.7.4 Hikma Pharmaceuticals Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.7.5 Hikma Pharmaceuticals Recent Development
11.8 WOCKHARDT
11.8.1 WOCKHARDT Company Details
11.8.2 WOCKHARDT Business Overview
11.8.3 WOCKHARDT Chronic Spontaneous Urticaria Drug Treatment Introduction
11.8.4 WOCKHARDT Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.8.5 WOCKHARDT Recent Development
11.9 AbbVie, Inc.
11.9.1 AbbVie, Inc. Company Details
11.9.2 AbbVie, Inc. Business Overview
11.9.3 AbbVie, Inc. Chronic Spontaneous Urticaria Drug Treatment Introduction
11.9.4 AbbVie, Inc. Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.9.5 AbbVie, Inc. Recent Development
11.10 Cipla Inc.
11.10.1 Cipla Inc. Company Details
11.10.2 Cipla Inc. Business Overview
11.10.3 Cipla Inc. Chronic Spontaneous Urticaria Drug Treatment Introduction
11.10.4 Cipla Inc. Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.10.5 Cipla Inc. Recent Development
11.11 F. Hoffmann La Roche Ltd.
11.11.1 F. Hoffmann La Roche Ltd. Company Details
11.11.2 F. Hoffmann La Roche Ltd. Business Overview
11.11.3 F. Hoffmann La Roche Ltd. Chronic Spontaneous Urticaria Drug Treatment Introduction
11.11.4 F. Hoffmann La Roche Ltd. Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.11.5 F. Hoffmann La Roche Ltd. Recent Development
11.12 Teva Pharmaceutical Industries, Ltd.
11.12.1 Teva Pharmaceutical Industries, Ltd. Company Details
11.12.2 Teva Pharmaceutical Industries, Ltd. Business Overview
11.12.3 Teva Pharmaceutical Industries, Ltd. Chronic Spontaneous Urticaria Drug Treatment Introduction
11.12.4 Teva Pharmaceutical Industries, Ltd. Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.12.5 Teva Pharmaceutical Industries, Ltd. Recent Development
11.13 Pfizer, Inc.
11.13.1 Pfizer, Inc. Company Details
11.13.2 Pfizer, Inc. Business Overview
11.13.3 Pfizer, Inc. Chronic Spontaneous Urticaria Drug Treatment Introduction
11.13.4 Pfizer, Inc. Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.13.5 Pfizer, Inc. Recent Development
11.14 Novartis AG
11.14.1 Novartis AG Company Details
11.14.2 Novartis AG Business Overview
11.14.3 Novartis AG Chronic Spontaneous Urticaria Drug Treatment Introduction
11.14.4 Novartis AG Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.14.5 Novartis AG Recent Development
11.15 Eli Lilly and Company
11.15.1 Eli Lilly and Company Company Details
11.15.2 Eli Lilly and Company Business Overview
11.15.3 Eli Lilly and Company Chronic Spontaneous Urticaria Drug Treatment Introduction
11.15.4 Eli Lilly and Company Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.15.5 Eli Lilly and Company Recent Development
11.16 Allergan
11.16.1 Allergan Company Details
11.16.2 Allergan Business Overview
11.16.3 Allergan Chronic Spontaneous Urticaria Drug Treatment Introduction
11.16.4 Allergan Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.16.5 Allergan Recent Development
11.17 Lupin
11.17.1 Lupin Company Details
11.17.2 Lupin Business Overview
11.17.3 Lupin Chronic Spontaneous Urticaria Drug Treatment Introduction
11.17.4 Lupin Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
11.17.5 Lupin Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Chronic Spontaneous Urticaria Drug Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Antihistamine
Table 3. Key Players of Dupixent
Table 4. Key Players of Other
Table 5. Global Chronic Spontaneous Urticaria Drug Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Chronic Spontaneous Urticaria Drug Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Chronic Spontaneous Urticaria Drug Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Chronic Spontaneous Urticaria Drug Treatment Market Share by Region (2019-2024)
Table 9. Global Chronic Spontaneous Urticaria Drug Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Chronic Spontaneous Urticaria Drug Treatment Market Share by Region (2025-2030)
Table 11. Chronic Spontaneous Urticaria Drug Treatment Market Trends
Table 12. Chronic Spontaneous Urticaria Drug Treatment Market Drivers
Table 13. Chronic Spontaneous Urticaria Drug Treatment Market Challenges
Table 14. Chronic Spontaneous Urticaria Drug Treatment Market Restraints
Table 15. Global Chronic Spontaneous Urticaria Drug Treatment Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Chronic Spontaneous Urticaria Drug Treatment Market Share by Players (2019-2024)
Table 17. Global Top Chronic Spontaneous Urticaria Drug Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Spontaneous Urticaria Drug Treatment as of 2023)
Table 18. Ranking of Global Top Chronic Spontaneous Urticaria Drug Treatment Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Chronic Spontaneous Urticaria Drug Treatment Revenue (CR5 and HHI) & (2019-2024)
Table 20. Global Key Players of Chronic Spontaneous Urticaria Drug Treatment, Headquarters and Area Served
Table 21. Global Key Players of Chronic Spontaneous Urticaria Drug Treatment, Product and Application
Table 22. Global Key Players of Chronic Spontaneous Urticaria Drug Treatment, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Chronic Spontaneous Urticaria Drug Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Chronic Spontaneous Urticaria Drug Treatment Revenue Market Share by Type (2019-2024)
Table 26. Global Chronic Spontaneous Urticaria Drug Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Chronic Spontaneous Urticaria Drug Treatment Revenue Market Share by Type (2025-2030)
Table 28. Global Chronic Spontaneous Urticaria Drug Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Chronic Spontaneous Urticaria Drug Treatment Revenue Market Share by Application (2019-2024)
Table 30. Global Chronic Spontaneous Urticaria Drug Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Chronic Spontaneous Urticaria Drug Treatment Revenue Market Share by Application (2025-2030)
Table 32. North America Chronic Spontaneous Urticaria Drug Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Chronic Spontaneous Urticaria Drug Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Chronic Spontaneous Urticaria Drug Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Chronic Spontaneous Urticaria Drug Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Chronic Spontaneous Urticaria Drug Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 47. Mylan N. V. Company Details
Table 48. Mylan N. V. Business Overview
Table 49. Mylan N. V. Chronic Spontaneous Urticaria Drug Treatment Product
Table 50. Mylan N. V. Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 51. Mylan N. V. Recent Development
Table 52. Sanofi Company Details
Table 53. Sanofi Business Overview
Table 54. Sanofi Chronic Spontaneous Urticaria Drug Treatment Product
Table 55. Sanofi Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 56. Sanofi Recent Development
Table 57. GlaxoSmithKline Company Details
Table 58. GlaxoSmithKline Business Overview
Table 59. GlaxoSmithKline Chronic Spontaneous Urticaria Drug Treatment Product
Table 60. GlaxoSmithKline Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 61. GlaxoSmithKline Recent Development
Table 62. Bayer Company Details
Table 63. Bayer Business Overview
Table 64. Bayer Chronic Spontaneous Urticaria Drug Treatment Product
Table 65. Bayer Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 66. Bayer Recent Development
Table 67. Merck Company Details
Table 68. Merck Business Overview
Table 69. Merck Chronic Spontaneous Urticaria Drug Treatment Product
Table 70. Merck Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 71. Merck Recent Development
Table 72. Aurobindo Pharma Company Details
Table 73. Aurobindo Pharma Business Overview
Table 74. Aurobindo Pharma Chronic Spontaneous Urticaria Drug Treatment Product
Table 75. Aurobindo Pharma Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 76. Aurobindo Pharma Recent Development
Table 77. Hikma Pharmaceuticals Company Details
Table 78. Hikma Pharmaceuticals Business Overview
Table 79. Hikma Pharmaceuticals Chronic Spontaneous Urticaria Drug Treatment Product
Table 80. Hikma Pharmaceuticals Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 81. Hikma Pharmaceuticals Recent Development
Table 82. WOCKHARDT Company Details
Table 83. WOCKHARDT Business Overview
Table 84. WOCKHARDT Chronic Spontaneous Urticaria Drug Treatment Product
Table 85. WOCKHARDT Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 86. WOCKHARDT Recent Development
Table 87. AbbVie, Inc. Company Details
Table 88. AbbVie, Inc. Business Overview
Table 89. AbbVie, Inc. Chronic Spontaneous Urticaria Drug Treatment Product
Table 90. AbbVie, Inc. Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 91. AbbVie, Inc. Recent Development
Table 92. Cipla Inc. Company Details
Table 93. Cipla Inc. Business Overview
Table 94. Cipla Inc. Chronic Spontaneous Urticaria Drug Treatment Product
Table 95. Cipla Inc. Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 96. Cipla Inc. Recent Development
Table 97. F. Hoffmann La Roche Ltd. Company Details
Table 98. F. Hoffmann La Roche Ltd. Business Overview
Table 99. F. Hoffmann La Roche Ltd. Chronic Spontaneous Urticaria Drug Treatment Product
Table 100. F. Hoffmann La Roche Ltd. Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 101. F. Hoffmann La Roche Ltd. Recent Development
Table 102. Teva Pharmaceutical Industries, Ltd. Company Details
Table 103. Teva Pharmaceutical Industries, Ltd. Business Overview
Table 104. Teva Pharmaceutical Industries, Ltd. Chronic Spontaneous Urticaria Drug Treatment Product
Table 105. Teva Pharmaceutical Industries, Ltd. Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 106. Teva Pharmaceutical Industries, Ltd. Recent Development
Table 107. Pfizer, Inc. Company Details
Table 108. Pfizer, Inc. Business Overview
Table 109. Pfizer, Inc. Chronic Spontaneous Urticaria Drug Treatment Product
Table 110. Pfizer, Inc. Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 111. Pfizer, Inc. Recent Development
Table 112. Novartis AG Company Details
Table 113. Novartis AG Business Overview
Table 114. Novartis AG Chronic Spontaneous Urticaria Drug Treatment Product
Table 115. Novartis AG Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 116. Novartis AG Recent Development
Table 117. Eli Lilly and Company Company Details
Table 118. Eli Lilly and Company Business Overview
Table 119. Eli Lilly and Company Chronic Spontaneous Urticaria Drug Treatment Product
Table 120. Eli Lilly and Company Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 121. Eli Lilly and Company Recent Development
Table 122. Allergan Company Details
Table 123. Allergan Business Overview
Table 124. Allergan Chronic Spontaneous Urticaria Drug Treatment Product
Table 125. Allergan Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 126. Allergan Recent Development
Table 127. Lupin Company Details
Table 128. Lupin Business Overview
Table 129. Lupin Chronic Spontaneous Urticaria Drug Treatment Product
Table 130. Lupin Revenue in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024) & (US$ Million)
Table 131. Lupin Recent Development
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
Table 135. Authors List of This Report
List of Figures
Figure 1. Chronic Spontaneous Urticaria Drug Treatment Picture
Figure 2. Global Chronic Spontaneous Urticaria Drug Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Chronic Spontaneous Urticaria Drug Treatment Market Share by Type: 2023 VS 2030
Figure 4. Antihistamine Features
Figure 5. Dupixent Features
Figure 6. Other Features
Figure 7. Global Chronic Spontaneous Urticaria Drug Treatment Market Size by Application (2024-2030) & (US$ Million)
Figure 8. Global Chronic Spontaneous Urticaria Drug Treatment Market Share by Application: 2023 VS 2030
Figure 9. Children Case Studies
Figure 10. Adult Case Studies
Figure 11. Chronic Spontaneous Urticaria Drug Treatment Report Years Considered
Figure 12. Global Chronic Spontaneous Urticaria Drug Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Chronic Spontaneous Urticaria Drug Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Chronic Spontaneous Urticaria Drug Treatment Market Share by Region: 2023 VS 2030
Figure 15. Global Chronic Spontaneous Urticaria Drug Treatment Market Share by Players in 2023
Figure 16. Global Top Chronic Spontaneous Urticaria Drug Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Spontaneous Urticaria Drug Treatment as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Chronic Spontaneous Urticaria Drug Treatment Revenue in 2023
Figure 18. North America Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Chronic Spontaneous Urticaria Drug Treatment Market Share by Country (2019-2030)
Figure 20. United States Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Chronic Spontaneous Urticaria Drug Treatment Market Share by Country (2019-2030)
Figure 24. Germany Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Chronic Spontaneous Urticaria Drug Treatment Market Share by Region (2019-2030)
Figure 32. China Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Chronic Spontaneous Urticaria Drug Treatment Market Share by Country (2019-2030)
Figure 40. Mexico Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Chronic Spontaneous Urticaria Drug Treatment Market Share by Country (2019-2030)
Figure 44. Turkey Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. UAE Chronic Spontaneous Urticaria Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Mylan N. V. Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 48. Sanofi Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 49. GlaxoSmithKline Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 50. Bayer Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 51. Merck Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 52. Aurobindo Pharma Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 53. Hikma Pharmaceuticals Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 54. WOCKHARDT Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 55. AbbVie, Inc. Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 56. Cipla Inc. Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 57. F. Hoffmann La Roche Ltd. Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 58. Teva Pharmaceutical Industries, Ltd. Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 59. Pfizer, Inc. Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 60. Novartis AG Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 61. Eli Lilly and Company Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 62. Allergan Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 63. Lupin Revenue Growth Rate in Chronic Spontaneous Urticaria Drug Treatment Business (2019-2024)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
